1,721,089 research outputs found
sj-docx-2-tah-10.1177_20406207221088462 – Supplemental material for Changing paradigms of hemophilia care across larger specialized treatment centers in the European region
No full textSupplemental material, sj-docx-2-tah-10.1177_20406207221088462 for Changing paradigms of hemophilia care across larger specialized treatment centers in the European region by Jerzy Windyga, Ana Boban, Irena Zupan, Niamh O’Connell and Cedric Hermans in Therapeutic Advances in Hematology</p
sj-docx-1-tah-10.1177_20406207221088462 – Supplemental material for Changing paradigms of hemophilia care across larger specialized treatment centers in the European region
No full textSupplemental material, sj-docx-1-tah-10.1177_20406207221088462 for Changing paradigms of hemophilia care across larger specialized treatment centers in the European region by Jerzy Windyga, Ana Boban, Irena Zupan, Niamh O’Connell and Cedric Hermans in Therapeutic Advances in Hematology</p
sj-docx-1-tah-10.1177_20406207211040345 – Supplemental material for Challenges of biological monitoring in a hemophilia A patient without inhibitors on emicizumab undergoing major orthopedic surgery: a case report
No full textSupplemental material, sj-docx-1-tah-10.1177_20406207211040345 for Challenges of biological monitoring in a hemophilia A patient without inhibitors on emicizumab undergoing major orthopedic surgery: a case report by Louise Guillaume, Marie-Astrid van Dievoet, Catherine Lambert and Cedric Hermans in Therapeutic Advances in Hematology</p
sj-docx-1-tah-10.1177_20406207231218624 – Supplemental material for The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study
No full textSupplemental material, sj-docx-1-tah-10.1177_20406207231218624 for The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study by Margareth C. Ozelo, Cedric Hermans, Manuel Carcao, Benoît Guillet, Joan Gu, Randy Guerra, Leilei Tang and Kate Khair in Therapeutic Advances in Hematology</p
sj-eps-2-tah-10.1177_20406207231184323 – Supplemental material for Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
No full textSupplemental material, sj-eps-2-tah-10.1177_20406207231184323 for Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study by Carmen Escuriola Ettingshausen, Cedric Hermans, Pål A. Holme, Ana R. Cid, Kate Khair, Johannes Oldenburg, Claude Négrier, Jaco Botha, Aurelia Lelli and Jerzy Windyga in Therapeutic Advances in Hematology</p
sj-docx-1-tah-10.1177_20406207231184323 – Supplemental material for Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
No full textSupplemental material, sj-docx-1-tah-10.1177_20406207231184323 for Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study by Carmen Escuriola Ettingshausen, Cedric Hermans, Pål A. Holme, Ana R. Cid, Kate Khair, Johannes Oldenburg, Claude Négrier, Jaco Botha, Aurelia Lelli and Jerzy Windyga in Therapeutic Advances in Hematology</p
sj-eps-3-tah-10.1177_20406207231184323 – Supplemental material for Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
No full textSupplemental material, sj-eps-3-tah-10.1177_20406207231184323 for Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study by Carmen Escuriola Ettingshausen, Cedric Hermans, Pål A. Holme, Ana R. Cid, Kate Khair, Johannes Oldenburg, Claude Négrier, Jaco Botha, Aurelia Lelli and Jerzy Windyga in Therapeutic Advances in Hematology</p
sj-docx-1-tah-10.1177_20406207231166779 – Supplemental material for Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ≽40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
No full textSupplemental material, sj-docx-1-tah-10.1177_20406207231166779 for Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ≽40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study by Mark T. Reding, Ingrid Pabinger, Pål Andrè Holme, Monika Maas Enriquez, Maria Elisa Mancuso, Shadan Lalezari, Wolfgang Miesbach, Giovanni Di Minno, Robert Klamroth and Cedric Hermans in Therapeutic Advances in Hematology</p
Optimal management of hemophilic arthropathy and hematomas
No full textSébastien Lobet,1,2 Cedric Hermans,1 Catherine Lambert1 1Hemostasis-Thrombosis Unit, Division of Hematology, 2Division of Physical Medicine and Rehabilitation, Cliniques Universitaires Saint-Luc, Brussels, Belgium Abstract: Hemophilia is a hematological disorder characterized by a partial or complete deficiency of clotting factor VIII or IX. Its bleeding complications primarily affect the musculoskeletal system. Hemarthrosis is a major hemophilia-related complication, responsible for a particularly debilitating chronic arthropathy, in the long term. In addition to clotting factor concentrates, usually prescribed by the hematologist, managing acute hemarthrosis and chronic arthropathy requires a close collaboration between the orthopedic surgeon and physiotherapist. This collaboration, comprising a coagulation and musculoskeletal specialist, is key to effectively preventing hemarthrosis, managing acute joint bleeding episodes, assessing joint function, and actively treating chronic arthropathy. This paper reviews, from a practical point of view, the pathophysiology, clinical manifestations, and treatment of hemarthrosis and chronic hemophilia-induced arthropathy for hematologists, orthopedic surgeons, and physiotherapists. Keywords: hemophilia, arthropathy, hemarthrosis, hematoma, physiotherapy, target join
Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015
No full textThe 6(th) Haemophilia Global Summit was held in Prague, Czech Republic, in September 2015. The programme was designed by an independent Scientific Steering Committee of haemophilia experts and aimed to share optimal management strategies for haemophilia at all life stages, explore recent potential advances in the management of haemophilia A and B and discuss challenges in haemophilia care. In this supplement from the meeting, Dan Hart reviews the lessons that can be learnt from cost-constrained environments with regard to improving care for people with haemophilia globally. Sébastien Lobet discusses the importance of physical activity for optimising care and Roseline d'Oiron and Jan Blatný consider the role of real-world data in understanding the effect of treatment in a clinical setting over the long term and the true impact of treatment on the day-to-day life of the patient. Gili Kenet addresses the current challenges relating to the optimal management of prophylaxis, and Gerry Dolan and Cedric Hermans discuss the value of pharmacokinetic (PK) parameters in informing treatment decisions. Cedric Hermans and Valérie Libotte explore the importance of considering social and occupational development factors as an integral part of haemophilia care, and Jan Astermark reviews key strategies to predict and prevent inhibitor development
- …
